1.Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J: Amyloid-beta: a crucial factor in Alzheimer’s disease. Med Princ Pract 2015, 24:1–10.
2.Jha MK, Park DH, Kook H, Lee IK, Lee WH, Suk K: Metabolic Control of Glia-Mediated Neuroinflammation. Curr Alzheimer Res 2016, 13:387–402.
3.Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, et al: Current and emerging avenues for Alzheimer’s disease drug targets. J Intern Med 2019, 286:398–437.
4.Guo C, Sun L, Chen X, Zhang D: Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res 2013, 8:2003–2014.
5.Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, Fang EF: Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms. Trends Neurosci 2017, 40:151–166.
6.Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, Lautrup S, Hasan-Olive MM, Caponio D, Dan X, et al: Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat Neurosci 2019, 22:401–412.
7.Lanzillotta C, Di Domenico F, Perluigi M, Butterfield DA: Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. CNS Drugs 2019.
8.Wang H, Shen Y, Chuang H, Chiu C, Ye Y, Zhao L: Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices. Curr Alzheimer Res 2019, 16:659–674.
9.Finneran DJ, Nash KR: Neuroinflammation and fractalkine signaling in Alzheimer’s disease. J Neuroinflammation 2019, 16:30.
10.Dionisio-Santos DA, Olschowka JA, O’Banion MK: Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease. J Neuroinflammation 2019, 16:74.
11.Fan Z, Brooks DJ, Okello A, Edison P: An early and late peak in microglial activation in Alzheimer’s disease trajectory. Brain 2017, 140:792–803.
12.Lue LF, Beach TG, Walker DG: Alzheimer’s Disease Research Using Human Microglia. Cells 2019, 8.
13.Sofroniew MV, Vinters HV: Astrocytes: biology and pathology. Acta Neuropathol 2010, 119:7–35.
14.Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ: Astrocytes in Alzheimer’s disease. Neurotherapeutics 2010, 7:399–412.
15.Fu W, Shi D, Westaway D, Jhamandas JH: Bioenergetic mechanisms in astrocytes may contribute to amyloid plaque deposition and toxicity. J Biol Chem 2015, 290:12504–12513.
16.Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015, 21:443–454.
17.Lee C, Kim KH, Cohen P: MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med 2016, 100:182–187.
18.Zarse K, Ristow M: A mitochondrially encoded hormone ameliorates obesity and insulin resistance. Cell Metab 2015, 21:355–356.
19.Hu BT, Chen WZ: MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-beta/Smad pathway. Eur Rev Med Pharmacol Sci 2018, 22:7156–7163.
20.Li H, Ren K, Jiang T, Zhao GJ: MOTS-c attenuates endothelial dysfunction via suppressing the MAPK/NF-kappaB pathway. Int J Cardiol 2018, 268:40.
21.Zhai D, Ye Z, Jiang Y, Xu C, Ruan B, Yang Y, Lei X, Xiang A, Lu H, Zhu Z, et al: MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA. Mol Immunol 2017, 92:151–160.
22.Yan Z, Zhu S, Wang H, Wang L, Du T, Ye Z, Zhai D, Zhu Z, Tian X, Lu Z, Cao X: MOTS-c inhibits Osteolysis in the Mouse Calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation. Pharmacol Res 2019, 147:104381.
23.Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, Tortelli R, Capozzo R, Bisceglia P, Dimitri A, et al: The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset. Expert Opin Biol Ther 2018, 18:25–35.
24.Heitz F, Morris MC, Divita G: Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009, 157:195–206.
25.Guidotti G, Brambilla L, Rossi D: Cell-Penetrating Peptides: From Basic Research to Clinics. Trends Pharmacol Sci 2017, 38:406–424.
26.Jiang J, Peng Y, He Z, Wei L, Jin W, Wang X, Chang M: Intrahippocampal injection of Cortistatin–14 impairs recognition memory consolidation in mice through activation of sst2, ghrelin and GABAA/B receptors. Brain Res 2017, 1666:38–47.
27.Paxinos G, Franklin KBJ, Franklin KBJ: The mouse brain in stereotaxic coordinates. 2nd edn. San Diego: Academic Press; 2001.
28.Jiang JH, He Z, Peng YL, Jin WD, Wang Z, Mu LY, Chang M, Wang R: Phoenixin–14 enhances memory and mitigates memory impairment induced by Abeta1–42 and scopolamine in mice. Brain Res 2015, 1629:298–308.
29.Liu H, Zhang W, Ma L, Fan L, Gao F, Ni J, Wang R: The improved blood-brain barrier permeability of endomorphin–1 using the cell-penetrating peptide synB3 with three different linkages. Int J Pharm 2014, 476:1–8.
30.Han RW, Zhang RS, Xu HJ, Chang M, Peng YL, Wang R: Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Abeta(1)(-)(4)(2) in mice novel object and object location recognition tasks. Neuropharmacology 2013, 70:261–267.
31.Vasconcelos AR, Yshii LM, Viel TA, Buck HS, Mattson MP, Scavone C, Kawamoto EM: Intermittent fasting attenuates lipopolysaccharide-induced neuroinflammation and memory impairment. J Neuroinflammation 2014, 11:85.
32.Zakaria R, Wan Yaacob WM, Othman Z, Long I, Ahmad AH, Al-Rahbi B: Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer’s disease. Physiol Res 2017, 66:553–565.
33.Kim YE, Hwang CJ, Lee HP, Kim CS, Son DJ, Ham YW, Hellstrom M, Han SB, Kim HS, Park EK, Hong JT: Inhibitory effect of punicalagin on lipopolysaccharide-induced neuroinflammation, oxidative stress and memory impairment via inhibition of nuclear factor-kappaB. Neuropharmacology 2017, 117:21–32.
34.Cho CF, Wolfe JM, Fadzen CM, Calligaris D, Hornburg K, Chiocca EA, Agar NYR, Pentelute BL, Lawler SE: Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nat Commun 2017, 8:15623.
35.Bohmova E, Machova D, Pechar M, Pola R, Venclikova K, Janouskova O, Etrych T: Cell-penetrating peptides: a useful tool for the delivery of various cargoes into cells. Physiol Res 2018, 67:S267-S279.
36.Cai Z, Hussain MD, Yan LJ: Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci 2014, 124:307–321.
37.Yang Y, Gao H, Zhou H, Liu Q, Qi Z, Zhang Y, Zhang J: The role of mitochondria-derived peptides in cardiovascular disease: Recent updates. Biomed Pharmacother 2019, 117:109075.
38.Catorce MN, Gevorkian G: LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals. Curr Neuropharmacol 2016, 14:155–164.
39.Kasza A, Penke B, Frank Z, Bozso Z, Szegedi V, Hunya A, Nemeth K, Kozma G, Fulop L: Studies for Improving a Rat Model of Alzheimer’s Disease: Icv Administration of Well-Characterized beta-Amyloid 1–42 Oligomers Induce Dysfunction in Spatial Memory. Molecules 2017, 22.
40.Park SJ, Jung HJ, Son MS, Jung JM, Kim DH, Jung IH, Cho YB, Lee EH, Ryu JH: Neuroprotective effects of INM–176 against lipopolysaccharide-induced neuronal injury. Pharmacol Biochem Behav 2012, 101:427–433.
41.Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, Reed JC: Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003, 423:456–461.
42.Zhao ST, Zhao L, Li JH: Neuroprotective Peptide humanin inhibits inflammatory response in astrocytes induced by lipopolysaccharide. Neurochem Res 2013, 38:581–588.
43.Gong Z, Tas E, Muzumdar R: Humanin and age-related diseases: a new link? Front Endocrinol (Lausanne) 2014, 5:210.